CAS: 188399-46-4; 2-Amino-9-((1R,3S,4R)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)-1H-Purin-6(9H)-One
该化合物是一个核分子类比,具有很强的抗病毒活动,具体针对乙型肝炎病毒(HBV)DNA聚合酶.作为Entecavir的抗菌剂,它表现出对乙型肝炎复制抑制的高度选择性,同时表现出对主机细胞DNA合成的最小影响.它的机制包括竞争抑制病毒反转转录酶,并将其纳入病毒DNA,导致链条终止.Ent-Entecavir的特点是它具有很强的抗抗药性,成为长期乙型肝炎治疗的强有力选择.该化合物通常用于口腔管理,提供有利的药源特性,包括持续的生物利用率和长期细胞内的半衰期,确保持续的抗病毒效力.
- 英文名称2-Amino-9-((1R,3S,4R)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)-1H-Purin-6(9H)-One
- 中文名称2-氨基-1,9-二氢-9-[(1R,3S,4R)-4-羟基-3-(羟基甲基)-2-亚甲基环戊基]-6H-嘌呤-6-酮
- IUPAC名称2-amino-9-((1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1,9-dihydro-6H-purin-6-one
- 其它别名[1R-(1α,3α,4β)]-2-Amino-1,9-Dihydro-9-[4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl]-6H-Purin-6-One; 6H-Purin-6-One, 2-Amino-1,9-Dihydro-9-[(1R,3S,4R)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl]-; 2-Amino-1,9-Dihydro-9-[(1R,3S,4R)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl]-6H-Purin-6-One; 2-Amino-9-[(1R,3S,4R)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylidenecyclopentyl]-3H-Purin-6-One; Enantiomer Enantiomer F; Entecavir Impurity 4/(1R,3S,4R)-Entecavir/2-Amino-9-((1R,3S,4R)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)-1,9-Dihydro-6H-Purin-6-One; Ent-Entecavir; 2-Amino-9-((1R,3S,4R)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)-1H-Purin-6(9H)-One
- CAS编号188399-46-4
- MFCD编号:MFCD16660347
- 分子式:C12H15N5O3分子量:277.28
- 产品CID: 955964
- 同类组份化合物CAS142217-69-4 (free)209216-23-9 (hydrate)911138-73-3 (maleate)188399-46-4 (enantiomer)
- 产品分类Chemistry → Asymmetric Synthesis → Chiral Building Blocks | Amides | Alkenyls | Inhibitors/Agonists → Anti-infection → HBV | Alcohols | Purines | Aromatic Heterocycles | Amines
物理性质
上下游产品
(1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol (3S,5R)-7-(trimethylsilyl)hept-1-en-6-yne-3,5-diol (3S,5R)-5-(tert-butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol (3S,5R)-5-(tert-butyldimethylsilyloxy)hept-1-en-6-yn-3-ol合成工艺路线路线简述
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905399001-1,3-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021 Jan 2. doi: 10.1007/s10620-020-06725-1. Epub ahead of print.
11:616023. doi: 10.3389/fmicb.2020.616023.
3: Manolakopoulos S, Kranidioti H, Kourikou A, Deutsch MM, Triantos C, Tsolias C, Manesis EK, Mathou N, Alexopoulou A, Hadziyannis E, Papatheodoridis G. Long- term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. Liver Int. 2021 Jan;41(1):48-57. doi: 10.1111/liv.14654. 12(11):1076-1088. doi: 10.4254/wjh.v12.i11.1076.
📝 需求与反馈
尽可能描述清楚需求与问题信息
